A Phase I Study of ZEN003694 plus Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer


Full Title

A Phase 1b Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide or Abiraterone in Patients with Metastatic Castration- Resistant Prostate Cancer


The purpose of this study is to investigate the safety and tolerability of the new drug ZEN003694 when combined with enzalutamide in men with metastatic castration-resistant prostate cancer (advanced cancer which has continued to grow at low testosterone levels). ZEN003694 is designed to treat cancer by inhibiting a family of proteins called BET proteins. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic castration-resistant prostate cancer that has continued to grow despite abiraterone and/or enzalutamide.
  • Patients may not have received chemotherapy for metastatic castration-resistant prostate cancer.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Wassim Abida at 646-422-4633.